In the News ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax How BTK inhibitors treat mantle cell lymphoma MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients What to know about mantle cell lymphoma Majority of patients responded in CAR T-cell trial for mantle cell lymphoma ARCHIVED: CAR T-cell therapy effective for relapsed mantle cell lymphoma patients Novel combination provides more effective treatment option for mantle cell lymphoma Present Title & Affiliation Primary Appointment Professor, Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX Professor, Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX Dual/Joint/Adjunct Appointment Puddin Clarke Professorship in Multiple Myeloma Research, Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX Professor, Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX Professor, Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX Founding and Current Director, Mantle Cell Lymphoma Program of Excellence, Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX Research Interests 1
Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF
Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, et al
Its very low bioavailability limits the interest of a supplementation
